- Previous Close
39.72 - Open
38.61 - Bid 27.10 x 200
- Ask 46.87 x 200
- Day's Range
36.41 - 38.94 - 52 Week Range
29.10 - 68.21 - Volume
171,044 - Avg. Volume
629,266 - Market Cap (intraday)
2.119B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.30 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
93.88
Apogee Therapeutics, Inc., a clinical stage biotechnology company, advances novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD which is in phase 2; for the treatment of asthma and EoE which is in phase 1. It also develops APG279 which is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra, for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
www.apogeetherapeutics.comRecent News: APGE
View MorePerformance Overview: APGE
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APGE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APGE
View MoreValuation Measures
Market Cap
2.31B
Enterprise Value
1.80B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.22
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.46%
Return on Equity (ttm)
-33.22%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-182.15M
Diluted EPS (ttm)
-3.30
Balance Sheet and Cash Flow
Total Cash (mrq)
520.65M
Total Debt/Equity (mrq)
1.65%
Levered Free Cash Flow (ttm)
-113.42M